Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 14/20 | 0.63 |
| ▸ | GLP1R | P43220 | 3/20 | 0.63 |
| ▸ | GIPR | P48546 | 3/20 | 0.63 |
| ▸ | GCG | P01275 | 8/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951195 | 0.89 | GCGR (0.73) | GCGRGLP1RGIPRGCG | |
| SCHEMBL9951078 | 0.89 | GCGR (0.73) | GCGRGLP1RGIPRGCG | |
| SCHEMBL9951083 | 0.89 | GCGR (0.73) | GCGRGLP1RGIPRGCG | |
| SCHEMBL9951493 | 0.89 | GCGR (0.74) | GCGRGCG | |
| SCHEMBL9951176 | 0.89 | GCGR (0.74) | GCGRGCG | |
| SCHEMBL9950980 | 0.89 | GCGR (0.74) | GCGRGCG | |
| SCHEMBL9951868 | 0.86 | GCGR (0.74) | GCGRGLP1RGIPRGCG | |
| SCHEMBL9951279 | 0.86 | GCGR (0.74) | GCGRGLP1RGIPRGCG | |
| SCHEMBL9951402 | 0.86 | GCGR (0.74) | GCGRGLP1RGIPRGCG | |
| SCHEMBL9952206 | 0.84 | GCGR (0.71) | GCGRGLP1RGIPRGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655331-A1 | GLUCAGON RECEPTOR MODULATORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | claimed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2655331-A1 | GLUCAGON RECEPTOR MODULATORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094338-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCGR 2/4885GLP1R 1/4885GIPR 4/4885 |
| US-20120165343-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCGR 2/4885GLP1R 1/4885GIPR 4/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GLP1R 1/4885GIPR 3/4885 |
| US-20150266861-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCGR 2/4885GLP1R 1/4885GIPR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.